Risk-to-benefit ratio of inhaled corticosteroids in patients with copd

As Juno’s setback demonstrated this summer, CAR-T treatments pose a safety risk. The engineered cells, put back into the patient’s body, can work so furiously that the patient has a serious immune reaction, called cytokine release syndrome. Kite reported today that two patients died in the midst of cytokine release syndrome, one from a rare immune malfunction, the other from cardiac arrest. Kite and others administering CAR-T cells treat the syndrome with steroids or with the immunosuppressive drug tocilizumab (Actemra). Chang called the ratio of risk to benefit “favorable.”

Risk-to-benefit ratio of inhaled corticosteroids in patients with copd

risk-to-benefit ratio of inhaled corticosteroids in patients with copd

Media:

risk-to-benefit ratio of inhaled corticosteroids in patients with copdrisk-to-benefit ratio of inhaled corticosteroids in patients with copdrisk-to-benefit ratio of inhaled corticosteroids in patients with copdrisk-to-benefit ratio of inhaled corticosteroids in patients with copdrisk-to-benefit ratio of inhaled corticosteroids in patients with copd

http://buy-steroids.org